Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takako Inoue

Showing results (71-80 of 144) with videos related to

Pageof 15
Sort By:
Investigational New Drugs|June 20, 2020
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumabMotohiro Tamiya, Kei Kunimasa, Kazumi Nishino, et al.
Journal of Clinical Microbiology|August 19, 2025
Evaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversionTakanori Suzuki, Chiharu Ohue, Osamu Arai, et al.
Lung Cancer Management|April 30, 2020
Switching from first or second generation EGFR-TKI to osimertinib in <i>EGFR</i> mutation-positive NSCLCFumio Imamura, Takako Inoue, Kei Kunimasa, et al.
Anticancer Research|October 7, 2017
The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes ThereafterKenji Nakahama, Shun-Ichi Isa, Akihiro Tamiya, et al.
In Vivo (Athens, Greece)|June 25, 2018
Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After NivolumabKenji Nakahama, Akihiro Tamiya, Shun-Ichi Isa, et al.
Journal of Thoracic Disease|August 3, 2018
Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lungKazumi Nishino, Shuichi Ohe, Masanori Kitamura, et al.
The Oncologist|October 22, 2025
Kinetics and Management of Adverse Events Associated With Lorlatinib After 5 Years of Follow-Up in the CROWN StudyGeoffrey Liu, Benjamin J Solomon, Julien Mazieres, et al.
Molecular and Clinical Oncology|August 17, 2017
Impact of <i>in vitro</i> chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resectionYuki Akazawa, Masahiko Higashiyama, Kazumi Nishino, et al.
Thoracic Cancer|November 11, 2024
Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case reportKei Kunimasa, Akito Miyazaki, Motohiro Tamiya, et al.
Oncotarget|November 10, 2018
Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Pageof 15

Showing results (71-80 of 144) with videos related to

Sort By:
Pageof 15
Investigational New Drugs|June 20, 2020
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumabMotohiro Tamiya, Kei Kunimasa, Kazumi Nishino, et al.
Journal of Clinical Microbiology|August 19, 2025
Evaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversionTakanori Suzuki, Chiharu Ohue, Osamu Arai, et al.
Lung Cancer Management|April 30, 2020
Switching from first or second generation EGFR-TKI to osimertinib in <i>EGFR</i> mutation-positive NSCLCFumio Imamura, Takako Inoue, Kei Kunimasa, et al.
Anticancer Research|October 7, 2017
The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes ThereafterKenji Nakahama, Shun-Ichi Isa, Akihiro Tamiya, et al.
In Vivo (Athens, Greece)|June 25, 2018
Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After NivolumabKenji Nakahama, Akihiro Tamiya, Shun-Ichi Isa, et al.
Journal of Thoracic Disease|August 3, 2018
Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lungKazumi Nishino, Shuichi Ohe, Masanori Kitamura, et al.
The Oncologist|October 22, 2025
Kinetics and Management of Adverse Events Associated With Lorlatinib After 5 Years of Follow-Up in the CROWN StudyGeoffrey Liu, Benjamin J Solomon, Julien Mazieres, et al.
Molecular and Clinical Oncology|August 17, 2017
Impact of <i>in vitro</i> chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resectionYuki Akazawa, Masahiko Higashiyama, Kazumi Nishino, et al.
Thoracic Cancer|November 11, 2024
Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case reportKei Kunimasa, Akito Miyazaki, Motohiro Tamiya, et al.
Oncotarget|November 10, 2018
Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Pageof 15